Skp2 and Skp2B team up against Rb and p53

Cell Division

Volumn 6, Issue , 2011, Pages

  Germain, Doris ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651538370     PISSN: None     EISSN: 17471028     Source Type: Journal    
DOI: 10.1186/1747-1028-6-1     Document Type: Note

References (46)

1. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001, 2:731-7. 10.1038/35096061, 11584300.
2. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002, 2:910-7. 10.1038/nrc950, 12459729.
3. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002, 3:11-20. 10.1038/nrm714, 11823794.
4. Toyashima H, Hunter T. p27, a novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21. Cell 1994, 78:67-74. 10.1016/0092-8674(94)90573-8, 8033213.
5. Serrano M, Hannon G, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707. 10.1038/366704a0, 8259215.
6. Sherr CJ. Cancer cell cycles. Science 1996, 274:1672-7. 10.1126/science.274.5293.1672, 8939849.
7. Zhou P, Howley PM. Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. Mol Cell 1998, 2:571-80. 10.1016/S1097-2765(00)80156-2, 9844630.
8. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ. SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box. Cell 1996, 86:263-274. 10.1016/S0092-8674(00)80098-7, 8706131.
9. Kipreos ET, Lander LE, Wing JP. cul-1 Is Required for Cell Cycle Exit in C. elegans and Identifies a Novel Gene Family. Cell Vol 1996, 85:829-839.
10. Feldman RM, Correll CC, Kaplan KB, Deshaies RJ. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p [see comments]. Cell 1997, 91:221-30. 10.1016/S0092-8674(00)80404-3, 9346239.
11. Skowyra D, Koepp D, Kamura T, Conrad M, Conaway R, Conaway JW, Elledge S, Harper JW. Reconstitution of G1 cyclin ubiquitination with complexes containingt SCFgrr1 and Rbx1. Science 1999, 284:662-665. 10.1126/science.284.5414.662, 10213692.
12. Ohta T, Michel JJ, Schottelius AJ, Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999, 3:535-41. 10.1016/S1097-2765(00)80482-7, 10230407.
13. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000, 102:549-52. 10.1016/S0092-8674(00)00077-5, 11007473.
14. Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex [see comments]. Cell 1997, 91:209-19. 10.1016/S0092-8674(00)80403-1, 9346238.
15. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999, 1:193-9. 10.1038/12013, 10559916.
16. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol 1999, 1:207-14. 10.1038/12027, 10559918.
17. Harper JW. Protein destruction: adapting roles for Cks proteins. Curr Biol 2001, 11:R431-5. 10.1016/S0960-9822(01)00253-6, 11516665.
18. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002, 110:633-41. 151109, 12208864.
19. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001, 98:5043-8. 10.1073/pnas.081474898, 33160, 11309491.
20. Loda M, Cukor BS, Tam W, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in agressive colorectal carcinomas. Nat Med 1997, 3:231-234. 10.1038/nm0297-231, 9018245.
21. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell 2008, 29:217-31. 10.1016/j.molcel.2007.11.036, 18243116.
22. Grossman SR. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001, 268:2773-8. 10.1046/j.1432-1327.2001.02226.x, 11358491.
23. Ganiatsas S, Dow R, Thompson A, Schulman B, Germain D. A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene 2001, 20:3641-50. 10.1038/sj.onc.1204501, 11439327.
24. Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 2005, 24:3448-58. 10.1038/sj.onc.1208328, 15782142.
25. Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 2003, 9:2613-9.
26. Dowen SE, Scott A, Mukherjee G, Stanley MA. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer 2003, 105:326-30. 10.1002/ijc.11066, 12704665.
27. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. Mod Pathol 2002, 15:1227-35. 10.1097/01.MP.0000036589.99516.D6, 12429803.
28. Umanskaya K, Radke S, Chander H, Monardo R, Xu X, Pan ZQ, O'Connell MJ, Germain D. Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor. Mol Cell Biol 2007, 27:7615-22. 10.1128/MCB.01239-07, 2169057, 17785450.
29. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 1999, 96:6947-52. 10.1073/pnas.96.12.6947, 22022, 10359819.
30. Mussi P, Liao L, Park SE, Ciana P, Maggi A, Katzenellenbogen BS, Xu J, O'Malley BW. Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland. Proc Natl Acad Sci USA 2006, 103:16716-21. 10.1073/pnas.0607768103, 1636521, 17065319.
31. Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B attenuates p53 function by inhibiting prohibitin. EMBO reports 2010, 11:222-225.
32. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003, 278:47853-61. 10.1074/jbc.M305171200, 14500729.
33. Wang S, Nath N, Adlam M, Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 1999, 18:3501-10. 10.1038/sj.onc.1202684, 10376528.
34. Wang S, Zhang B, Faller DV. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. Embo J 2002, 21:3019-28. 10.1093/emboj/cdf302, 126057, 12065415.
35. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002, 21:8388-96. 10.1038/sj.onc.1205944, 12466959.
36. Wang S, Zhang B, Faller DV. BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. Embo J 2004, 23:2293-303. 10.1038/sj.emboj.7600231, 419909, 15141164.
37. Choi D, Lee SJ, Hong S, Kim IH, Kang S. Prohibitin interacts with RNF2 and regulates E2F1 function via dual pathways. Oncogene 2008, 27:1716-25. 10.1038/sj.onc.1210806, 17873902.
38. Artal-Sanz M, Tsang WY, Willems EM, Grivell LA, Lemire BD, van der Spek H, Nijtmans LG. The mitochondrial prohibitin complex is essential for embryonic viability and germline function in Caenorhabditis elegans. J Biol Chem 2003, 278:32091-9. 10.1074/jbc.M304877200, 12794069.
39. Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA, Wright EG. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res 2001, 265:262-73. 10.1006/excr.2001.5166, 11302691.
40. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, Rapp UR, Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005, 7:837-43. 10.1038/ncb1283, 16041367.
41. Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Lower B, Wunderlich FT, von Kleist-Retzow JC, Waisman A, Westermann B, Langer T. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev 2008, 22:476-88. 10.1101/gad.460708, 2238669, 18281461.
42. Schleicher M, Shepherd BR, Suarez Y, Fernandez-Hernando C, Yu J, Pan Y, Acevedo LM, Shadel GS, Sessa WC. Prohibitin-1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence. J Cell Biol 2008, 180:101-12. 10.1083/jcb.200706072, 2213620, 18195103.
43. Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 2007, 26:1757-68. 10.1038/sj.onc.1209967, 16964284.
44. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R, Lam EW, Bevan CL. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004, 23:2996-3004. 10.1038/sj.onc.1207444, 14968116.
45. Peng X, Mehta R, Wang S, Chellappan S, Mehta RG. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 2006, 66:7361-9. 10.1158/0008-5472.CAN-06-1004, 16849588.
46. Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003, 278:41355-66. 10.1074/jbc.M302830200, 12904306.